Navigating the EMA’s Centralised Marketing Authorisation Procedure

The Centralised Marketing Authorisation Procedure is the key pathway for obtaining drug approval across the European Union (EU) through a single application submitted to the European Medicines Agency (EMA). This regulatory route is essential for companies aiming to commercialize their medicinal products across all EU member states, as well as Iceland, Liechtenstein, and Norway. This comprehensive guide outlines the eligibility criteria, application components, submission process, and regulatory timelines to help applicants successfully navigate the centralised procedure.

What is the Centralised Procedure?

The Centralised Marketing Authorisation Procedure allows sponsors to submit one application, undergo a single scientific evaluation by the EMA’s Committee for Medicinal Products for Human Use (CHMP), and receive a binding decision from the European Commission (EC) valid in all EU and EEA countries. This harmonised process ensures consistency in drug approval, especially for innovative and high-impact medicinal products.

Primary Benefits of the Centralised Procedure:

• One application, one evaluation, and one marketing authorisation valid throughout the EU/EEA
• Access to all EU countries simultaneously
• Accelerated review options for priority products
• Scientific support through pre-submission meetings with EMA

Eligibility Criteria for Centralised Authorisation:

The centralised procedure is mandatory or optional based on product type:

Mandatory for:

• Biotechnological medicinal products
• Advanced therapy medicinal products (ATMPs)
• Orphan medicinal products
• New active substances for cancer, neurodegenerative disorders, diabetes, auto-immune diseases, etc.
• Medicines for HIV/AIDS, viral hepatitis, and rare diseases

Optional for:

• Products offering significant therapeutic, scientific, or technical innovation
• Medicines in the interest of public health at EU level

Step-by-Step Application Process:

1. Eligibility Request (Optional but Recommended): Sponsors can request a confirmation from EMA on whether their product qualifies for centralised procedure.
2. Pre-submission Meetings: Schedule early meetings with EMA 6-7 months before submission to clarify regulatory expectations, dossier requirements, and procedural timelines.
3. Submission of MAA (Marketing Authorisation Application): Use the electronic Common Technical Document (eCTD) format via the EU Submission Portal.
4. Validation Phase (0–30 days): EMA checks the completeness and correctness of the application.
5. Scientific Evaluation (Day 1–210): Conducted in two phases by CHMP, with the possibility of clock-stops for sponsor responses.
6. Final Opinion and EC Decision (Day 277–300): EMA submits its opinion to the EC for legally binding decision across the EU.

Content of the Marketing Authorisation Application:

The application must include:

• Module 1: Regional administrative information, product information, and labeling
• Module 2: Summaries of quality, non-clinical, and clinical data
• Module 3: Quality data including manufacturing and control
• Module 4: Non-clinical study reports
• Module 5: Clinical study reports (efficacy and safety)

Scientific Committees Involved:

• CHMP (Committee for Medicinal Products for Human Use): Core committee responsible for evaluating human medicines
• PRAC (Pharmacovigilance Risk Assessment Committee): Assesses safety and risk-benefit balance
• CAT (Committee for Advanced Therapies): Evaluates ATMPs
• COMP (Committee for Orphan Medicinal Products): Recommends orphan drug designation

Timelines and Clock-Stops:

The standard evaluation timeframe is 210 active days, with additional clock-stop periods for sponsor responses. The overall process from submission to European Commission decision can take up to 12 months, or faster under accelerated assessment (150 days) for products of major public health interest.

Labelling and Translations:

Product information (SmPC, labelling, and package leaflet) must be submitted in all 24 official EU languages before authorisation can be granted. EMA coordinates translation review and quality checks across member states.

Post-Authorisation Commitments:

• Risk Management Plans (RMP): Mandatory for most new products to monitor post-market safety
• Post-authorisation Safety Studies (PASS): To evaluate safety in real-world settings
• Renewals: After 5 years, the authorisation must be renewed for indefinite validity
• Variations: Any post-approval change must be submitted through variation procedures (Type IA, IB, II)

Special Considerations for SMEs and Orphan Drugs:

The EMA provides regulatory, administrative, and financial support to small and medium-sized enterprises (SMEs). Orphan drugs benefit from protocol assistance, fee reductions, and 10 years of market exclusivity.

Best Practices for a Successful Application:

1. Initiate early communication with EMA and request scientific advice if necessary.
2. Ensure dossier quality, completeness, and adherence to current guidelines and templates.
3. Utilize the EMA Pre-Authorisation Procedural Advice Manual for step-by-step submission rules.
4. Prepare for GxP inspections during validation and review phases.
5. Align clinical study design with EMA guidelines and CHMP expectations.

Harmonization with Global Regulations:

The EMA’s centralised procedure aligns closely with global regulatory frameworks such as those of the USFDA and CDSCO. This allows multinational companies to prepare core dossiers usable across multiple regulatory agencies.

Conclusion:

The EMA’s Centralised Marketing Authorisation Procedure offers a streamlined route to pan-European approval, critical for the launch of innovative medicines. Understanding the eligibility rules, dossier structure, regulatory interactions, and post-approval commitments is essential for regulatory success. For ongoing updates and document alignment, platforms like Stability Studies and reference to Pharma GMP compliance tools provide much-needed guidance. In-house teams can further benefit from structured documentation available at Pharma SOPs for optimal readiness during EMA review processes.